Cite
HARVARD Citation
Li, J. et al. (2020). Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. Lancet gastroenterology and hepatology. pp. 548-560. [Online].